quality control is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== Scientific analysis == Due to its lethality and its widespread presence in the genus Amanita, which is found across the globe, β-Amanitin has been extensively studied in the field of protein biochemistry. In particular, William Lipscomb, Nobel laureate, greatly contributed to characterizing this protein. Not only did Lipscomb determine how to successfully retrieve and purify this life-threatening protein, but he also determined the molecular structure by X-ray crystallography in a time before this technique was widely utilized.
== Precautions == THF is a relatively acutely nontoxic solvent, with the median lethal dose (LD50) comparable to that for acetone. However, chronic exposure is suspected of causing cancer. Reflecting its remarkable solvent properties, it penetrates the skin, causing rapid dehydration. It is highly flammable. THF dissolves or penetrates most polymer glove materials in a very short period of time; only Linear low-density polyethylene (LLDPE) laminated gloves are capable of protecting against it for long time periods, similar to most ketones. Polyvinyl alcohol (PVA) coated gloves are capable of providing protection for nearly an hour, but because PVA is water soluble they are only effective in low humidity environments and when working with anhydrous solvents. Even very thick nitrile or nitrile-neoprene gloves degrade in under 10 minutes. One danger posed by THF is its tendency to form explosive peroxides upon reaction with air:
Narrated by Juliet Stevenson (later to narrate many Horizon documentaries), directed by John Simmons, produced by Martine Benoit, made by Geofilms 27 September How They Built the Channel Tunnel, looking at the construction of the two crossover places of the tunnel, as big as two football fields, forty metres below the sea bed; AR Dykes, the President of the British Institution of Structural Engineers in 1976; Gordon Crighton, engineering director of TML, David Wallis, project manager of UK Tunnels of TML; the French end of the tunnel was at Beussingue; it took five years; Colin Kirkland, technical director of Eurotunnel; Richard Lewis of Markhams, a steel fabricator in Chesterfield; geologist Malcolm Bolton of the University of Cambridge; Douglas Parkes of Ove Arup; Stewart Campbell of the HSE; tunnelling began from Folkestone in October 1987; many tunnellers were from North East England and the Irish, such as Jim Ahern; 2,000 tonnes of chalk per hour came out of the tunnel during 1989; the laser guidance was made by Zed Systems of London; 440 metres of tunnel per week could be built; tunnel concrete segments were cast on the Isle of Grain, in Kent; nine workers died in accidents - seven on the English side; there are two cross-over caverns; the English cavern was built from the service tunnel, before the main tunnels arrived; the caverns are 21 metres wide, 16 metres high and 147 metres long, with two movable walls; the British Tunnelling Society; Alan Myers, construction manager of the crossover for UK Tunnels; civil engineer John King.
"Attogram sensing of trinitrotoluene with a self-assembled molecular gelator". Journal of the American Chemical Society. 134 (10): 4834–4841. doi:10.1021/ja210728c. PMID 22352376. SS Babu, VK Praveen, Ajayaghosh, Ayyappanpillai (2014). “Functional π-gelators and their applications”. Chem. Rev. 2014, 114, 4, 1973-2129. https://doi.org/10.1021/cr400195e R, D, Mukhopadhyay.; and Ajayaghosh, Ayyappanpillai (2015). “Living supramolecular polymerization”. Science 2015, 349, 241.doi:10.1126/science.aac7422 S, Prasanthkumar.; S, Ghosh.; V, C, Nair.; A, Saeki.; S, Seki.; and Ajayaghosh Ayyappanpillai (2015). “Organic Donor-Acceptor Assemblies to Coaxial p-n Heterojunctions with High Photoconductivity”. Angew. Chem., Int. Ed. 2015, 54, 946-950. https://doi.org/10.1002/anie.201408831. B, Vedhanarayanan.; V, S, Nair.; V, C, Nair.; and Ajayaghosh, Ayyappanpillai (2016). “Formation of Coaxial Nanocables with Amplified Supramolecular Chirality through an Interaction between Carbon Nanotubes and a Chiral p-Gelator”. Angew. Chem., Int. Ed. 2016, 55, 10345-10349. https://doi.org/10.1002/anie.201605354. V, S, Nair.; R, D, Mukhopadhyay.; A, Saeki.; S, Seki.; and Ajayaghosh, Ayyappanpillai (2016). “A p-Gel Scaffold for Assembling Fullerene to Photoconducting Supramolecular Rods: Non-Equilibrium Self-Assembly of C60 in a p-Gel”. Science Advances 2016, 2, e1600142. doi:10.1126/sciadv.1600142 R, D, Mukhopadhyay.; B, Vedhanarayanan.; and Ajayaghosh, Ayyappanpillai (2017). “Creation of 'Rose Petal' and 'Lotus Leaf' Effects on Alumina by Surface Functionalization and Metal Ion Coordination”. Angew.
Sources: en.wikipedia.org
=== Antihistamine === Cidoxepin is under development by Elorac, Inc. for the treatment of chronic urticaria (hives). As of 2017, it is in phase II clinical trials for this indication. The drug was also under investigation for the treatment of allergic rhinitis, atopic dermatitis, and contact dermatitis, but development for these indications was discontinued.
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. The most common side effects include fatigue, peripheral neuropathy (nerve damage resulting in tingling or numbness), decreased appetite, rash, alopecia (hair loss), nausea, altered taste, diarrhea, dry eye, pruritus (itching) and dry skin. The fully humanized antibody was created by scientists at Agensys (part of Astellas) using Xenomice from Amgen; the linker technology holding the antibody and the toxin together was provided by and licensed from Seattle Genetics. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
All cells with mitochondria can take up ketones from the blood and reconvert them into acetyl-CoA, which can then be used as fuel in their citric acid cycles, as no other tissue can divert its oxaloacetate into the gluconeogenic pathway in the way that this can occur in the liver. Unlike free fatty acids, ketones can cross the blood–brain barrier and are therefore available as fuel for the cells of the central nervous system, acting as a substitute for glucose, on which these cells normally survive. The occurrence of high levels of ketones in the blood during starvation, a low carbohydrate diet, prolonged heavy exercise, or uncontrolled type 1 diabetes mellitus is known as ketosis, and, in its extreme form, in out-of-control type 1 diabetes mellitus, as ketoacidosis.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.